NEW YORK (GenomeWeb News) – Qiagen and Ventana Medical Systems jointly announced today that they have agreed to settle litigation regarding two expired patents covering human papillomavirus probes.
The firms said that they had mutually agreed to terms on Dec. 15 settling litigation of the expired patents, US Nos. 4,849,331 and 4,849,332.
Under terms of the settlement, Ventana agreed to pay Qiagen an undisclosed sum. In return, Qiagen acknowledged that pursuant to an asset purchase agreement signed Sept. 23, 2002, Ventana has lawfully succeeded to certain rights held by Beckman Coulter under a cross-licensing pact originally entered into between Institut Pasteur and Life Technologies and a separate agreement between Institut Pasteur and Beckman.